ChromaVision's ACIS cleared in US for broader diagnosis
This article was originally published in Clinica
Executive Summary
ChromaVision Medical Systems has received US FDA clearance to market its automated cellular imaging system (ACIS) for the analysis of immunohistochemical stains. The device, which already has 510(k) clearance for use with biochemical stains to screen blood for certain malignancies, can now be used to assess a wider spectrum of conditions including cancer and infectious diseases.